NRx Pharmaceuticals, Inc.

Equities

BRPA

US6294442099

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
3.14 ^USD	+0.64%		+3.97%	-31.74%

Apr. 18	NRx Pharmaceuticals Receives Notice of Listing Compliance From Nasdaq	MT
Apr. 18	Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Fed Policymakers Speeches	MT

Nrx Pharmaceuticals, Inc. Announces Director Resignation

June 21, 2022 at 06:05 am EDT

NRx Pharmaceuticals, Inc. announced that the Class I directors are Chaim Hurvitz and Daniel Troy, and their terms will expire at 2022 annual meeting of stockholders. Daniel Troy will not be standing for reelection to the Board.

Latest news about NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals Receives Notice of Listing Compliance From Nasdaq	Apr. 18	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday Ahead of Fed Policymakers Speeches	Apr. 18	MT
Top Premarket Decliners	Apr. 18	MT
NRx Pharmaceuticals Looking to Sell Shares to Fund General Corporate Activities; Shares Slump Premarket	Apr. 18	MT
NRx Pharmaceuticals Looking to Sell Shares to Fund General Corporate Activities, Working Capital	Apr. 17	MT
NRx Pharmaceuticals, Inc. Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics	Apr. 17	CI
NRx Pharmaceuticals, Inc. Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)	Apr. 15	CI
NRx Pharmaceuticals, Inc. Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression	Apr. 08	CI
Transcript : NRx Pharmaceuticals, Inc., Q4 2023 Earnings Call, Apr 01, 2024	Apr. 01
NRx Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Transcript : NRx Pharmaceuticals, Inc. - Shareholder/Analyst Call	Mar. 21
NRx Pharmaceuticals, Inc., Conversio Health, LLC and Nephron Pharmaceuticals Corporation Complete Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine)	Mar. 11	CI
NRX Pharmaceuticals Announces Last Patient, Last Visit in Its Phase 2B/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression	Mar. 04	CI
NRx Pharmaceuticals, Inc. Announces Completion of Enrollment of Its Phase 2b/3 Trial of NRx-101 in Suicidal Treatment Resistant Bipolar Depression	Jan. 22	CI
NRx Pharmaceuticals Gets Fast-Track Designation for NRX-101 UTI Treatment	Jan. 16	DJ
NRx Pharmaceuticals, Inc. Announces FDA Qualified Infectious Disease Product and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis	Jan. 16	CI
NRx Pharmaceuticals Says It Reached Nasdaq Listing Compliance	Jan. 02	MT
Transcript : NRx Pharmaceuticals, Inc. - Shareholder/Analyst Call	Dec. 28
Nrx Pharmaceuticals Announces Election of Janet Rehnquist to Its Board of Directors	Dec. 27	CI
Transcript : NRx Pharmaceuticals, Inc. - Shareholder/Analyst Call	Dec. 19
NRx Pharmaceuticals, Inc. Announces FDA Clearance of its Investigational New Drug Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections	Dec. 18	CI
Transcript : NRx Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
NRx Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
NRx Pharmaceuticals and Nephron Pharmaceuticals Announce Joint Agreement to Develop Intravenous Ketamine to Treat Suicidal Depression	Nov. 06	CI
NRx Pharmaceuticals Announces Signing of a Development Agreement for the Manufacture of Ketamine to Treat Suicidality and Depression	23-10-31	CI

Chart NRx Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.

Sector

Biotechnology & Medical Research

Calendar

2024-05-13 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.14 USD

Average target price

37.5 USD

Spread / Average Target

+1,094.27%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NRX PHARMACEUTICALS, INC.	-31.74%	32.72M
IQVIA HOLDINGS INC.	+1.12%	42.59B
MODERNA, INC.	+6.77%	40.65B
LONZA GROUP AG	+47.70%	40.57B
CELLTRION, INC.	-11.96%	26.77B
ICON PUBLIC LIMITED COMPANY	+6.01%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-24.92%	18.17B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.63%	11.7B
MEDPACE HOLDINGS, INC.	+27.16%	12.05B
UNITED THERAPEUTICS CORPORATION	+7.30%	11.1B

Other Biotechnology & Medical Research